Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways
Marine Drugs · 2025
DOI: 10.3390/md23010047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Jing Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China. Hauptthemen laut MEDLINE: NF-kappa B, Inflammatory Bowel Diseases, Anti-Inflammatory Agents, Toll-Like Receptors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, High-tech SMEs Innovation Capacity Improvement Project of Shandong Province, Key R&D Program of Shandong Province.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is characterized by uncontrolled, chronic relapsing inflammation in the gastrointestinal tract and has become a global healthcare problem. Here, we aimed to illustrate the anti-inflammatory activity and the underlying mechanism of methyl 3-bromo-4,5-dihydroxybenzoate (MBD), a compound derived from marine organisms, especially in IBD, using a zebrafish model. The results indicated that MBD could inhibit the inflammatory responses induced by CuSO4, tail amputation and LPS in zebrafish. Furthermore, MBD notably inhibited the intestinal migration of immune cells, enhanced the integrity of the gut mucosal barrier and improved intestinal peristalsis function in a zebrafish IBD model induced by trinitro-benzene-sulfonic acid (TNBS). In addition, MBD could inhibit ROS elevation induced by TNBS. Network pharmacology analysis, molecular docking, transcriptomics sequencing and RT-PCR were conducted to investigate the potential mechanism. The results showed that MBD could regulate the TLR/NF-κB pathways by inhibiting the mRNA expression of TNF-α, NF-κB, IL-1, IL-1β, IL6, AP1, IFNγ, IKKβ, MyD88, STAT3, TRAF1, TRAF6, NLRP3, NOD2, TLR3 and TLR4, and promoting the mRNA expression of IL4, IκBα and Bcl-2. In conclusion, these findings indicate that MBD could be a potential candidate for the treatment of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
- Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Jinan 250103, China.
- Institute of Physiology, Medical School, University of Pecs, H-7624 Pecs, Hungary.
- University Research and Innovation Center, Obuda University, H-1034 Budapest, Hungary.
ORCID-Profile: Lei Li, Attila Gabor Sik, Meng Jin, Rongchun Wang, Xiaobin Li
Förderung
- the National Natural Science Foundation of China
- High-tech SMEs Innovation Capacity Improvement Project of Shandong Province
- Key R&D Program of Shandong Province
- the Jinan Talent Project for Universities
- Taishan Scholars Program
- National Natural Science Foundation of China
- Key R&D Program of Shandong Province
- Jinan Talent Project for Universities
Zitieren
APA
Huang, J., Li, L., Xu, L., Feng, L., Wang, Y., Sik, A. G., Jin, M., Wang, R., Liu, K., & Li, X. (2025). Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. Marine Drugs. https://doi.org/10.3390/md23010047
Vancouver
Huang J, Li L, Xu L, Feng L, Wang Y, Sik AG, et al. Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. Marine Drugs. 2025. doi:10.3390/md23010047
BibTeX
@article{Huang2025,
author = {Huang, Jing and Li, Lei and Xu, Liyan and Feng, Lixin and Wang, Yuxin and Sik, Attila Gabor and Jin, Meng and Wang, Rongchun and Liu, Kechun and Li, Xiaobin},
title = {Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23010047}
}
EUVIMED